CIBC initiated coverage on shares of Acasti Pharma (NASDAQ:ACST) in a report published on Thursday, FirstToMarketsRatingsTable reports. The brokerage issued an outperform rating and a $7.00 target price on the biopharmaceutical company’s stock.
ACST has been the topic of several other research reports. Zacks Investment Research downgraded shares of Home Bancshares from a hold rating to a sell rating in a research note on Friday, June 7th. Aegis assumed coverage on shares of Acasti Pharma in a research note on Tuesday, July 9th. They set a buy rating on the stock. Oppenheimer reaffirmed a market perform rating on shares of Waste Management in a research note on Thursday. ValuEngine raised shares of WPP from a sell rating to a hold rating in a research note on Wednesday, June 19th. Finally, HC Wainwright reissued a buy rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus target price of $5.25.
Acasti Pharma stock opened at $1.71 on Thursday. Acasti Pharma has a 12-month low of $0.43 and a 12-month high of $1.80. The business’s fifty day moving average price is $1.13.
Acasti Pharma Company Profile
Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.
Featured Story: Buyback For Investors Defined
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.